BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, discovering a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.

Biotechnology

BenevolentAI

Joerg Moeller

Judit Molnar M.D.

James Malone

Anna Fullerton-Batten

Will Scrimshaw

Ivan Griffin

Anne Phelan

Leadership Team

Engineering Team

Data Science Team

Drug Discovery and Pharmacology

��

BenevolentAI

Org chart

Teams

Leadership Team

Engineering Team

Data Science Team

Drug Discovery and Pharmacology

Similar companies

��������

BenevolentAI

Org chart

Teams

Leadership Team

Engineering Team

Data Science Team

Drug Discovery and Pharmacology

Similar companies

��